Superworth

Exelixis EV/EBIT EXEL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Nov 2, 2026
16.8×
9-year median
16.3×
Against its 9-year history
52nd
percentile: 0 is its lowest day, 100 its highest
9-year range
9.6× to 189×
Peer median
23.8×

Exelixis' EV/EBIT is 16.8× as of Nov 2, 2026.

That is above its 9-year median of 16.3×, close to the middle of its last 9 years.

Over that time it ranged from 9.6× in Dec 2022 to 189× in Jul 2017.

The median for 10 biotech stocks of a similar size is 23.8×.

EV/EBIT over time

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far16.8×11.0×16.8×
202514.1×12.2×14.7×
202413.6×12.5×23.3×
202324.1×10.2×24.1×
20229.8×9.6×24.9×
202122.8×18.8×131×
202031.2×10.4×32.4×
201911.8×10.0×17.8×
201814.2×11.9×53.7×
201751.5×43.5×189×
2016n/m a value too high to mean anything
2015n/m a value too high to mean anything
2014n/m a value too high to mean anything
2013n/m a value too high to mean anything
20126.5×4.6×8.2×

Against its peers

Companies in Biotechnology nearest Exelixis' size, closest first, today.

Where Exelixis ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Exelixis

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.